Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections

Background: Influenza is a highly variable infection that can cause fatal complications. Universal approaches, such as general stimulation of the immune system to activate its natural antiviral capacities, seem to be a rational measure. Methods: A total of 410 patients with influenza-like infectio...

Full description

Bibliographic Details
Main Authors: Ivan I. Tokin, Vladimir V. Nikiforov, Pavel I. Shabalkin, Pavel V. Pimanchev, Julia A. Isakova, Valeriy V. Tsvetkov
Format: Article
Language:English
Published: International Medical Research and Development Corporation 2018-12-01
Series:International Journal of Biomedicine
Subjects:
Online Access:http://ijbm.org/articles/IJBM_8(4)_OA_12.pdf
_version_ 1818036102724845568
author Ivan I. Tokin
Vladimir V. Nikiforov
Pavel I. Shabalkin
Pavel V. Pimanchev
Julia A. Isakova
Valeriy V. Tsvetkov
author_facet Ivan I. Tokin
Vladimir V. Nikiforov
Pavel I. Shabalkin
Pavel V. Pimanchev
Julia A. Isakova
Valeriy V. Tsvetkov
author_sort Ivan I. Tokin
collection DOAJ
description Background: Influenza is a highly variable infection that can cause fatal complications. Universal approaches, such as general stimulation of the immune system to activate its natural antiviral capacities, seem to be a rational measure. Methods: A total of 410 patients with influenza-like infections (ILI) were randomly assigned to one of three treatment groups and one control group. Interferon gamma (IFN-γ) was administered by intranasal introduction of 1 to 3 drops into each nostril 5 times per day daily for 5 days. The first dose of investigational medicine was given within 48h of the onset of the influenza-like symptoms. One drop of the solution contains 1,000 IU of active substance. All patients received basic complex therapy without any antiviral or immunomodulating agents. The patients were followed up for 7 days. Treatment efficacy was evaluated by the mean duration of symptoms (MDS), the period of viral antigen detection (VAD) measured after 1-2 and 4-5 days of treatment, and the incidence of complications. We used conventional indicators to evaluate the safety of IFN-γ in the treatment of ILI. Results: The administration of 2 or 3 drops of IFN-γ in each nasal passage led to better outcomes manifested in the considerable (P<0.05) reduction of all acute respiratory symptoms, and therefore to a more rapid recovery. In these treatment groups, statistically significant decreases for MDS values, VAD period, and incidence of complications were registered. Intranasal IFN-γ in complex therapy of ILI was considered to be well tolerated and safe.
first_indexed 2024-12-10T07:05:37Z
format Article
id doaj.art-0ce03f67e58a4522b6589f72b569d693
institution Directory Open Access Journal
issn 2158-0510
2158-0529
language English
last_indexed 2024-12-10T07:05:37Z
publishDate 2018-12-01
publisher International Medical Research and Development Corporation
record_format Article
series International Journal of Biomedicine
spelling doaj.art-0ce03f67e58a4522b6589f72b569d6932022-12-22T01:58:11ZengInternational Medical Research and Development CorporationInternational Journal of Biomedicine2158-05102158-05292018-12-018432733210.21103/Article8(4)_OA12Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like InfectionsIvan I. Tokin0Vladimir V. Nikiforov1Pavel I. Shabalkin2Pavel V. Pimanchev3Julia A. Isakova4Valeriy V. Tsvetkov5Research Institute of Influenza; North-Western State Medical University named after I.I. Mechnikov; Saint Petersburg, Russia Pirogov Russian National Research Medical University; Moscow, RussiaN.N. Blokhin National Medical Research Center of Oncology; Moscow, RussiaSechenov First Moscow State Medical University; Moscow, RussiaScientific Clinical Centre of the Russian Railways; Moscow, RussiaResearch Institute of Influenza; Saint Petersburg RussiaBackground: Influenza is a highly variable infection that can cause fatal complications. Universal approaches, such as general stimulation of the immune system to activate its natural antiviral capacities, seem to be a rational measure. Methods: A total of 410 patients with influenza-like infections (ILI) were randomly assigned to one of three treatment groups and one control group. Interferon gamma (IFN-γ) was administered by intranasal introduction of 1 to 3 drops into each nostril 5 times per day daily for 5 days. The first dose of investigational medicine was given within 48h of the onset of the influenza-like symptoms. One drop of the solution contains 1,000 IU of active substance. All patients received basic complex therapy without any antiviral or immunomodulating agents. The patients were followed up for 7 days. Treatment efficacy was evaluated by the mean duration of symptoms (MDS), the period of viral antigen detection (VAD) measured after 1-2 and 4-5 days of treatment, and the incidence of complications. We used conventional indicators to evaluate the safety of IFN-γ in the treatment of ILI. Results: The administration of 2 or 3 drops of IFN-γ in each nasal passage led to better outcomes manifested in the considerable (P<0.05) reduction of all acute respiratory symptoms, and therefore to a more rapid recovery. In these treatment groups, statistically significant decreases for MDS values, VAD period, and incidence of complications were registered. Intranasal IFN-γ in complex therapy of ILI was considered to be well tolerated and safe.http://ijbm.org/articles/IJBM_8(4)_OA_12.pdfInfluenzainterferon gammarespiratory tract infectionantiviral capacities
spellingShingle Ivan I. Tokin
Vladimir V. Nikiforov
Pavel I. Shabalkin
Pavel V. Pimanchev
Julia A. Isakova
Valeriy V. Tsvetkov
Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections
International Journal of Biomedicine
Influenza
interferon gamma
respiratory tract infection
antiviral capacities
title Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections
title_full Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections
title_fullStr Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections
title_full_unstemmed Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections
title_short Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections
title_sort randomized controlled parallel design clinical study of the efficacy and safety of intranasal interferon gamma in treatment of influenza like infections
topic Influenza
interferon gamma
respiratory tract infection
antiviral capacities
url http://ijbm.org/articles/IJBM_8(4)_OA_12.pdf
work_keys_str_mv AT ivanitokin randomizedcontrolledparalleldesignclinicalstudyoftheefficacyandsafetyofintranasalinterferongammaintreatmentofinfluenzalikeinfections
AT vladimirvnikiforov randomizedcontrolledparalleldesignclinicalstudyoftheefficacyandsafetyofintranasalinterferongammaintreatmentofinfluenzalikeinfections
AT pavelishabalkin randomizedcontrolledparalleldesignclinicalstudyoftheefficacyandsafetyofintranasalinterferongammaintreatmentofinfluenzalikeinfections
AT pavelvpimanchev randomizedcontrolledparalleldesignclinicalstudyoftheefficacyandsafetyofintranasalinterferongammaintreatmentofinfluenzalikeinfections
AT juliaaisakova randomizedcontrolledparalleldesignclinicalstudyoftheefficacyandsafetyofintranasalinterferongammaintreatmentofinfluenzalikeinfections
AT valeriyvtsvetkov randomizedcontrolledparalleldesignclinicalstudyoftheefficacyandsafetyofintranasalinterferongammaintreatmentofinfluenzalikeinfections